HIV disease treatment in the era of HAART

Biomedicine and Pharmacotherapy

Volumn 53, Issue 2, 1999, Pages 93-105

  Bonfanti, P ^a   Capetti, A ^a   Rizzardini, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

HAART; HIV disease; Protease inhibitors

Indexed keywords

ABACAVIR; ADEFOVIR DIPIVOXIL; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; EFAVIRENZ; EMIVIRINE; INDINAVIR; KNI 764; KYNOSTATIN 272; MOZENAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW;

EID: 0033102496     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(99)80066-3     Document Type: Article

References (124)

1. 1 Pantaleo G, Graziosi C, Demarest J, Butini L, Montroni M, Fox CH, et al. HIV infection is active and progressive in lymphoid tissue during the clinically stage of disease. Nature 1993; 362 : 355-8.
2. 2 Ho DD, Neumann AS, Perelson, Chen W, Leonard JM, Markowitz M. Rapid turn over of plasma virions and CD4 lymphocytes in HIV infection. Nature 1995; 373 : 123-5.
3. 3 Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1. Nature 1995; 373 : 117-22.
4. 4 Saag MS, Holodniy M, Kuritzkes, O Brien W, Coombs R, Poscher ME, et al. HIV viral load markers in clinical practice. Nature Med 1996; 6 : 625-9.
5. 5 Mellors JW, Rinaldo CR, Gupta P, White RM, Todd J, Kingskey LA, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272 : 1167-70.
6. 6 Mellors JW, Kingsley LA, Rinaldo CR, Todd J, Hoo BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 112 : 573-9.
7. 7 O'Brien TR, Blattner WA, Waters D, Eystert E, Hilgartner MW, Cohen AR, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia cohort Study. JAMA 1996; 276 : 105-10.
8. 8 Mc Donald CK, Kuritzkes DR. Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med 1997; 157 : 951-9.
9. 9 Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV Protease inhibitors. Drugs 1996; 51 : 701-12.
10. 10 Hammer SM, Katzenstein DA, Hughes MD, Gundacker K, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 μL to 500 μL. N Engl J Med 1996; 335 : 1081-90.
11. 11 Delta Coordinating Committee. Delta: a randomized double-blind trial controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348 : 283-91.
12. 12 CAESAR Coordinating Committee. Randomized Trial of addition of lamivudine or lamivudine plus loviride to zidovudine containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349 : 1413-21.
13. 13 Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl Med 1997; 337 : 734-9.
14. 14 Carpenter C, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1996. JAMA 1996; 276 : 146-54.
15. 15 Carpenter C, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1997; 277 : 1962-9.
16. 16 BHIVA Guidelines Co-ordinating Committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349 : 1086-92.
17. 17 Hogg RS, Heath KV, Yip B, Craig KJ, O'Shangnessy MV, Schecter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279 : 450-4.
18. 18 Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998 : 1497-503.
19. 19 Wong JK, Hezareh M, Gunthard H, Havlir D, Ignacio CC, Spina C, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278 : 1291-5.
20. 20 Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir of HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278 : 1295-300.
21. 21 Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The efficacy of azidothimidine in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317 : 186-97.
22. 22 Fischl MA, Richman DD, Hansen N, Collier AC, Carey J, Para MF, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1(HIV) infection. A double-blind, placebo-controlled trial. Ann Intern Med 1990; 112 : 727-37.
23. 23 Fischl MA, Parker CB, Pettinelli C, Wulfsohn M, Hirsch MS, Collier AC, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 1990; 323 : 1009-14.
24. 24 State-of-the-art Conference on Azidothymidine Therapy for Early HIV Infection. Am J Med 1990; 89 : 335-44.
25. 25 Concorde Coordinating Committee. Concorde: MRC/ARNS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343 : 871-81.
26. 26 Volberding PA, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng T, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995; 333 : 401-7.
27. 27 Fischl MA, Stanley K, Collier AC, Arduino J, Stein DS, Feinber JE, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995; 122 : 24-32.
28. 28 Sande MA, Carpenter CCJ, Cobbs CG, Holmes KK, Sanford JP. Antiretroviral therapy for adult HIV-infected patients: recommendations from a state-of-the-art conference. JAMA 1993; 270 : 2583-9.
29. 29 Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, Stein DS, et al. Zidovudine alone or combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996; 335 : 1099-100.
30. 30 Flexner C. HIV Protease Inhibitors. N Engl J Med 1998; 338 : 1281-92.
31. 31 Collier AC, Coombs RW, Schoenfeld DA, Basset RL, Timpone J, Baruch A, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996; 334 : 1011-7.
32. 32 Borleffs JC, the CHEESE Study Team. First comparative study of saquinavir soft gel capsules vs. indinavir as part of triple therapy regimen (CHEESE) Abstract 387b. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb. 1-5; Chicago, USA.
33. 33 Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333 : 1534-9.
34. 34 Cameron DW, Heath-Chiozzi M, Danner S, Coher C, Kraucik S, Maurath C, et al. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351 : 543-9.
35. 35 Cohen C, Revicki DA, Nabulsi A, Sarocco PW, Jiang P. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease study Group. AIDS 1998; 12 : 1495-502.
36. 36 Hammer SM, Squires KE, Hughes MD, Grimes JM, Demetemer LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337 : 725-33.
37. 37 Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez J, McMahon D, et al. Simultaneos vs. sequential initiation of therapy with indinavir, zidovudine and lamivudine for HIV-1 infection. 100-week follow-up. JAMA 1998; 280 : 35-41.
38. 38 Moyle GJ, Youle M, Higgs C, Monaghan J, prince W, Charman S, et al. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients with HIV. J Clin Pharmacol 1998; 8 : 736-43.
39. 39 Jarvis B, Faulds D. Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs 1998; 56 : 147-67.
40. 40 De Clerq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV infection. Antiviral Res 1998; 38: 153-79.
41. 41 Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemoter 1993; 37 : 1207-13.
42. 42 D'aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Liou SH, et al. Nevirapine, zidovudine and didanosine compared with zidovudineand didanosine in patients with HIV-1 infection - a randomized, double blind, placebo controlled trial. Ann Intern Med 1996; 124 : 1019-30.
43. 43 Montaner JS, Reiss P, Cooper D, Vella S, Marris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. Italy, the Netherlands, Canada, Australia Study. JAMA 1998; 279 : 930-7.
44. 44 Bellman PC. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed. AIDS 1998; 12 : 1333-40.
45. 45 Kagan S, Jemsek J, Martin DG, Pierone G, Manion DJ, Lee SR, et al. Initial effectiveness and tolerability of nelfinavir (NFV) in combination with efavirenz (EFV, SUSTIVA, DMP 266) in antiretroviral therapy naive or nucleoside analogue experienced HIV-1 infected patients: characterization in a phase II, open-label, multi-center study at > 36 weeks Abstract I-102. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sept.; San Diego, USA.
46. 46 Havlir D, Hicks C, Kahn J, Riddler S, Lino Q, Ruiz N, et al. Durability of antiviral activity of efavirenz (EFV, DMP 266) in combination with indinavir (IDV) Abstract I-104. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sept.; San Diego, USA.
47. 47 Morales-Ramirez J, Tashima K, Hardy D, Johnson P, Nelson M, Staszewsky S, et al. A phase II multi-center, randomized, open label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV) versus EFV + zidovudine (ZDV) + lamivudine (3TC) versus IDV + ZDV + 3TC at > 36 weeks [DMP 266-006] Abstract I-103. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sept.; San Diego, USA.
48. 48 Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 1995; 267 : 483-9.
49. 49 Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995; 333 : 450-1.
50. 50 Carpenter JC, Fischl MA, Hammer SA, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection 1998. Updated recommendations of the International AIDS Society-USA Panel. JAMA 1998; 280 : 78-86.
51. 51 MMWR supplement. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Int Med 1998; 128 : 1079-100.
52. 52 Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bhat TN, Erickson JW, et al. Selection and analysis of HIV-1 variants with increased resistance in ABT-538, a novel protease inhibitor. J Virol 1995; 69 : 701-6.
53. 53 Molla A, Korneyeva M, Gao Q, Vasanonda S, Schipper PJ, Mo HM, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996; 2 : 760-6.
54. 54 Condra JH, Schleif WA, Blahy OM, Gabryelsky LY, Graham DM, Quintero JC, et al. In vivo emergence oh HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374 : 569-71.
55. 55 Hirsch MS, Conway B, D'Aquila R, Johnson VA, Brun Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection. Implications for clinical management. JAMA 1998; 279 : 1984-91.
56. 56 Gatti G, Di Biagio A, De Pascalis C, Pontali E, Bassetti M, Cruciani M, et al. High variability of indinavir parameters of systemic exposure in HIV patients observed prospectively in everyday clinical practice Abstract A-66. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sept.; San Diego, USA.
57. 57 Gatti G, Di Biagio A, Casazza R, Bassetti M, Cruciani M, Vella S, et al. Pharmacodynamic relationship between ritonavir side effects and its plasma concentrations Abstract A-75. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sept.; San Diego, USA.
58. 58 Lange J. Issues for the future of antiretroviral therapy. Antiviral Therapy 1997; 2 (Suppl 4); 71-83.
59. 59 Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998; 12 : 37-9.
60. 60 Henry K, Melroe H, Huebsch J, Hermundson J, levine C, Swensen L, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351 : 1328.
61. 61 Carr A, Samaras K, Chisolm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipdaemia, and insulin resistance. Lancet 1998; 352 : 1881-3.
62. 62 Kotler D, Heymsfield SB. HIV infection: a model chronic illness for studying wasting diseases. Am J Clin Nutr 1998; 68 : 519-20.
63. 63 Arribas JR, Gonzales-Garcia J, Ibanez C, Ruiz B, Pena JM, Esteban C, et al. Acute hepatitis in AIDS patients during ritonavir treatment Abstract 417. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb.; Chicago, USA.
64. 64 Rietsema WJ. Fever. Erythroderma, abdominal pain, and renal failure following initiation of indinavir therapy. CID 1997; 25 : 1268-9.
65. 65 Wong JK, Günthard HF, Havlir DV, Zang ZQ, Haase AT, Ignacio CC, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologie correlates of treatment failure. Proc Natl Acad Sci USA 1997; 94 : 12574-9.
66. 66 Günthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, et al. Human immunodeficiency viras replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998; 72 : 2422-8.
67. 67 Nijhuis M, Schipper P, Leitner T, Schuurman R, Boucher C, Albert J. During Development of Ritonavir Resistance, HIV-1 Evolution is Determined by Stochastic Processes Abstract I-80. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sept.; San Diego, USA.
68. 68 Perelson A. Mathematical models for describing drug resistance Abstract S-120. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial agents and Chemotherapy; 1997 Sept.; Toronto, Canada.
69. 69 De Jong MD, Veenstra J, Stilianakis N. Return to baseline values of HIV-1 RNA load during zidovudine treatment is associated with the emergence of K70R mutant virus Abstract 20. In: Program and abstracts of the 4th International HIV-Drug Resistance Workshop; 1995 July; Sardinia, Italy.
70. 70 Larder BA, Kellam P, Kemp SD. Zidovudine resistance predicted by direct detection of mutants in DNA from HIV-infected lymphocytes. AIDS 1991; 5 : 137-44.
71. 71 Mayers DL, Japour A.J, Arduino JM, Hammer SM, Reichman R, Wagner KF, et al. Dideoxynucleoside resistance emerges with prolonged zidovudine therapy. Antimicrob Agents Chemother 1994; 37 : 1207-3.
72. 72 Gao Q, Gu Z, Parniak M, Cameron J, Cammack N, Boucher C, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high level resistance to the (-) enantiomer of 2',3'-dideoxy,3'-thyacytidine. Antimicrob Agents chemother 1993; 37 : 1390-2.
73. 73 Miller V, Stürmer M, Staszewski S, Groschel B, Hertogs K, De Berthune MP, et al. The M184V mutation in HIV-1 reverse transcriptase conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue reverse transcriptase inhibitors. AIDS 1998; 12 : 705-12.
74. 74 Larder BA. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269 : 696-9.
75. 75 Eron JJ, Chow Y K, Caliendo AM, Videler J, Devore KM, Cooley TP, et al. Pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type-1 isolates in vivo. Antimicrob Agents Chemother 1993; 37 : 1480-7.
76. 76 Fitzgibbon JE, Howell RM, Haberzettl CA, Sperber SJ, Goche DS, Dubin DT, et al. Human immunodeficiency virus type-1 pol gene mutations which cause decreased susceptibility to 2'3'-dideoxycytidine. Antimicrob Agents Chemother 1992; 36 : 153-7.
77. 77 Gu Z, Gao Q, Fang H, Salomon H, Parniak MA, Goldberg E, et al. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy, 3'-thyacytydine. Antimicrob Agents Chemother 1994; 38 : 275-81.
78. 78 Sommadossi J.P. Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2',3' dideoxynucleoside analogues. J Infect Dis 1995; 171 : 588.
79. 79 Lacey SF, Larder BA. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro, 2',3'-dideoxythymidine in cell culture. Antimicrob Agents Chemother 1994; 38 : 1428-32.
80. 80 Larder BA. Reverse transcriptase inhibitors Abstract PL 3.1. In: Program and abstracts of the Fourth International Congress on Drug Therapy in HIV Infection; 1998 Nov.; Glasgow, Scotland.
81. 81 Lanier ER, Smilaey M, St. Clair MH, Pearce G, Spreen W, Cutrell A, et al. Phenotypic HIV resistance in vitro correlates with viral load response to abacavir (1592, ABC) in vivo Abstract 32289. In: Program and abstracts of the 12th World AIDS Conference; 1998 July; Geneva, Switzerland.
82. 82 Iversen AK. Multi-drug resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996; 70 : 1086-90.
83. 83 Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewsky S, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV working group. JAMA 1996; 276 : 1140.
84. 84 Arnold E, Ding J, Hughes SH, Hostomsky Z. Structures of DNA and RNA polymerases and their interaction with nucleic acid substrates. Curr Opin Struct Biol 1995; 5 : 27-38.
85. 85 Dueweke TJ, Pushkarskays T, Poppe SM, Swaney SM, Zao JQ, Chen IS, et al. A mutation in reverse transcriptase of bis (heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors Proc Natl Acad Sci USA 1993; 90 : 4713-7.
86. 86 Condra JH, Holder DJ, Schleif WA, Blahi OM, Danovich RM, Gabryelsky LY, et al. Genetic correlates to in vivo viral resistance to Indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996; 70 : 8270-6.
87. 87 Richman DD. New strategies to combat drug resistance. Hosp Pract 1996; 15 : 47-58.
88. 88 Jacobsen H, Hänggl M, Ott M, Duncan IB, Owen S, Andreoni M, et al. In vivo resistance to a human immunodeficiency virus type 1 protease inhibitor: mutations, kinetics and frequencies. J Infect Dis 1996; 173 : 1379-87.
89. 89 Patick AK. Genotypic analysis of HIV-1 variants isolated from patients treated with the protease inhibitor Nelfinavir alone or in combination with d4T or AZT and 3TC Abstract 10. In: Program and abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997; St. Petersburg, Florida.
90. 90 Mellors J. Patterns of phenotypic and genotypic cross-resistance among protease inhibitors in over 1.000 clinical isolates. In : Program and abstracts of the 12th World AIDS Conference; 1998 July; Geneva, Switzerland.
91. 91 Bodsworth NJ, Slade M, Ewan J, McNally L. Ritonavir and Indinavir Therapy at 28 weeks after Saquinavir therapy. Influence of HIV-1 protease mutations Abstract P-396. In: Program and abstracts of the 5th Congress on Retroviruses and Opportunistic Infections; 1998 Sept.; Chicago, USA.
92. 92 Carrillo A, Sham H, Norbeck D, Kempf D, Kohlbrenner W, Plattner J, et al. Mutation in the proteolytic sites is required for the growth of mutant HIV selected by ABT-378, a novel protease inhibitor Abstract 209. In: Program and abstracts of the 4th conference on Retroviruses and Opportunistic Infections; 1997 Jan.; Washington D.C., USA.
93. 93 Altice FL, Friedland GH. The era of adherence to HIV therapy. Ann Intern Med 1998; 129 : 503-5.
94. 94 Gilson I, Busalacchi M. Abacavir/efavirenz/adefovir salvage regimen for refractory HIV disease Abstract I-200. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sept.; San Diego, USA.
95. 95 Hill A, Gazzard B. Low frequency of genotypic mutations associated with resistance to AZT and 3TC after combination treatment with indinavir. Abs. 42197. In: Program and abstracts of the 12th World AIDS Conference; 1998 June 28-July 3; Geneva, Switzerland.
96. 96 Deeks SG. Retroviral therapy: issues in salvage therapy Abstract S-29. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sept.; San Diego, USA.
97. 97 Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. : Can HIV genotype determination can be useful for individualized adaptation of antiretroviral therapy? The VIRADAPT French Study. [Abs. OP 7.1] In: Program and abstracts of the Fourth International Congress on Drug Therapy in HIV Infection; 1998 Nov.; Glasgow, Scotland.
98. 98 Reijers MHE, Weverling GJ, Jurriaans S, Wit FW, Weigel HM, Ten Kate RW, et al. : Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998; 352 : 185-90.
99. 99 Havlir DV, Marschener IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998; 339 : 1261-8.
100. 100 Pialoux P, Raffi F, Brun-Vezinet F, Meiffredy U, Flandre P, Gastaut JA, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine and indinavir in previously untreated HIV-1-infected patients. N Engl J Med 1998; 339 : 1269-76.
101. 101 Clumeck N, Mundere J, Kabeya K, Konopnicki D, Sommerejns B, O'Doherty E, et al. MIRO: a randomized trial of three maintenance therapy with or without protease inhibitors after 4 months of triple or quadruple induction therapy Abstract OP 2.2. In: Program and abstracts of the Fourth International Congress on Drug Therapy in HIV Infection; 1998 Nov.; Glasgow, Scotland.
102. 102 Hammer SM. Using Nucleoside and Nucleotide Reverse Transcriptase Inhibitors Abs. PL7.3. In: Program and abstracts of the Fourth International Congress on Drug Therapy in HIV Infection; 1998 Nov.; Glasgow, Scotland.
103. 103 Montaner JSG, Harrigan PR, Jahnke N, Yip B, Hogg R, Montressori V, et al. Integrating Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) into Clinical Practice Abstract PL 7.2. In: Program and abstracts of the Fourth International Congress on Drug Therapy in HIV Infection; 1998 Nov.; Glasgow, Scotland.
104. 104 Henry K, Shaefer MS, Bellman P, Norris D, Wallace R, Sawyer G, et al. TARGET : preliminary data of effective switch/intensification treatment with Combivir™ and Ziagen™ in therapy-experienced adults Abstract I-98. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sept.; San Diego, USA.
105. 105 Hetherington S, Steel HM, Lafon S, Spreen W, Pearce G. Safety and tolerance of Abacavir (1592, ABC) alone and in combination therapy of HIV infection Abstract 12353. In: Program and abstracts of the 12th World AIDS Conference; 1998 July; Geneva, Switzerland.
106. 106 Kahn J, Lagakos S, Weng D, Winslow D, Hardy D, Beall G, et al. A multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of Adefovir Dipivoxil (ADV) when added to standard antiretroviral therapy (ART) Abstract I-108. In: Program and abstracts of the 38th Interscience Congress on Antimicrobial Agents and Chemotherapy; 1998 Sept.; San Diego, USA.
107. 107 Cherrington JM, Mulato AS, Lamy PD, Margot NA, Anton KE, Miller MD, et al. Adefovir Dipivoxil (bis-POM PMEA) therapy significantly decreases HIV RNA in patients with high-level AZT/3TC resistant HIV Abs. I-84. In: Program and abstracts of the 38th Interscience Congress on Antimicrobial Agents and Chemotherapy: 1998 Sept.; San Diego, USA.
108. 108 Miller MD, Margot NA, Anton KE, Mulato AS, Lamy PD, Cherrinton JM. HIV-1 expressing the 3TC-associated M184V mutation in reverse transcriptase shows increased susceptibility to Adefovir and PMPA independent of changes in Ki for the mutant RT Abstract I-123. In: Program and abstracts of the 38th Interscience Congress on Antimicrobial Agents and Chemotherapy; 1998 Sept.; San Diego, USA.
109. 109 Cassano P, DeWitt S, Hermans P, Kabeya K, Gerard M, Sommerijns B, et al. 141W94-AZT-3TC association: a novel protease inhibitor (PI) added to long-standing AZT-3TC or combined with new reverse transcriptase inhibitors (NRTIs) Abstract I-101. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sept.; San Diego, USA.
110. 110 Haubrich R. Phase 2 study of amprenavir, a novel protease inhibitor, in combination with zidovudine/3TC Abstract 12321. In: Program and abstracts of the 12th World AIDS Conference; 1998 July; Geneva, Switzerland.
111. + counts > 400 cells/(1 and viral load > 5,000 copies/mL Abstract 286*/12204. In: Program and abstracts of the 12th World AIDS Conference; 1998 July; Geneva, Switzerland.
112. 112 Rousseau F, Wang LH, Delehanty J, Hulett L, McCreedy B, Sommadossi JP, et al. Intracellular FTC-triphosphate levels correlate with the clinical antiviral activity of FTC Abstract OP 7.5. In: Program and abstracts of the Fourth International Congress on Drug Therapy in HIV Infection; 1998 Nov.; Glasgow, Scotland.
113. 113 Ruxrungtham K, Boone E, Ford H Jr, Driscoll JS, Davey RT, Lane HL. Potent activity of 2'-β-fluoro-2',3'-dideoxyadenosine against human immunodeficiency virus type 1 infection in PBL-SCID mice. Antimicrob Agents Chemother 1996; 40 : 2369-74.
114. 114 Brennan TM, Taylor DL, Bridges CG, Leyda JP, Tyms AS. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone or in combination with other anti-HIV compounds. Antivir Res 1995; 26 : 173-87.
115. 115 Hill E, Taylor N, Borroto-Esoda K. In vitro synergy studies with MKC 442, a non-nucleoside reverse transcriptase inhibitor Poster 49. In: Program and abstracts of the 11th International Conference on Antiviral Research; 1998 April; San Diego, USA.
116. 116 Szczech GM, Furman P, Painter GR. Safety assessment, in vitro and in vivo, and pharmacokinteics of MKC-442, a potent and selective non-nucleoside reverse transcriptase inhibitor of HIV-1. Antimicrob Agents Chemother, In press.
117. 117 Moxham CP, Szczech GM, Blum MR, Barry DW. Pharmacokinetics (PK) and safety of single escalating doses of MKC-442 in HIV-infected volunteers. [Poster 573]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan.; Washington DC, USA.
118. 118 Chong KT, Pagano PJ. In vitro combination of PNU-140690 a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob Agents Chemother 1997; 41 : 2367-73.
119. 119 Poppe SM, Slade DE, Chong KT, Kinshaw RR, Pagano PJ, Markowitz M, et al. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 1997; 41 : 1058-63.
120. 120 Turner SR, Strohbach JW, Tommasi RA, Aristoff PA, Johnson PD, Skulnick HI, et al. Tipranavir (PNU-140690): a potent, orally bioavailable non peptidic HIV protease inhibitor of the 5,6 dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 1998; 41 : 3467-76.
121. 121 Gong YF, Robinson B, Rose R, Deminie C, Spicer T, Markowitz M, et al. Antiviral activity and resistance profile of an HIV-1 protease inhibitor, BMS-232632 Abstract I-79. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sept.; San Diego, USA.
122. 122 Kato R, Yusa K, Gulnik SV, Bhat T, Hayashi H, Milsuya H, et al. Importance of molecular flexibility for the resistance of HIV-1 protease inhibitors Abstract 12277. In: Program and abstracts of the 12th World AIDS Conference; 1998 July; Geneva, Switzerland.
123. 123 Sato H, Shintani MS, Mimoto TM, Terashima KT, Hayashi H, Mitsuya H. In vitro antiviral activity and pharmacokinetic (PK) profiles of KNI 272 when combined with other protease inhibitors Abstract 12339. In: Program and abstracts of the 12th World AIDS Conference; 1998 July; Geneva, Switzerland.
124. 124 Ueno T, Mimoto T, Shintani M, Sato H, Yusa K, Mitsuya H, et al. Anti-HIV-1 activity of and HIV-1 resistance profiles against JE-2147 and (KNI-764), a novel inhibitor of HIV-1 protease. Abs. 12270. In: Program and abstracts of the 12th World AIDS Conference; 1998 July; Geneva, Switzerland.